BB Biotech Accelerates Portfolio Overhaul and Outperforms NAV in Strong Q1 2026

The investment company BB Biotech restructured its portfolio more actively in the first three months of the year than ever before. Eleven new stocks were added, the investment guidelines were expanded, and the share price outpaced the net asset value in all currencies. This is according to BB Biotech’s quarterly report.

BB Biotech had a good start of the year

The biotech investment company’s stock achieved a total return of 4.1 percent in Swiss francs, 5.2 percent in euros, and 3.2 percent in US dollars in the first quarter – outperforming the Nasdaq Biotechnology Index (NBI) in all three reporting currencies. Net asset value (NAV) developed more modestly, declining by 0.6 percent in Swiss francs, rising marginally by 0.1 percent in euros, and falling by 1.5 percent in dollars. All returns include the dividend of CHF 2.25 per share paid out in March. This was announced by BB Biotech in a press release.

The share price’s outperformance of 4.7 percentage points relative to the NAV in Swiss francs has had a noticeable effect on the valuation gap: The discount between the share price and the net asset value decreased to 6.9 percent at the end of March, down from 10.8 percent at the end of 2025. Management interprets this as an expression of increased investor confidence and a clearer perception of the portfolio’s quality.

BB Biotech reported a net loss of CHF 21 million for the quarter – a significant improvement compared to the CHF 241 million loss in the same period last year. According to the company, the negative result was primarily due to portfolio reallocations, timing issues in the establishment of new large-cap positions, and individual share price reactions to clinical updates that slightly missed market expectations. The result was mitigated by Merck’s acquisition of Terns Pharmaceuticals, announced shortly before the end of the quarter.

Most active portfolio restructuring in years

The first quarter marked one of the most active restructuring phases in BB Biotech’s recent history. Eleven new positions were established, several existing holdings were increased, and other investments were sold in whole or in part. As a result, the portfolio grew from 24 to 30 stocks.

The return of large-cap stocks to the portfolio is noteworthy. With Regeneron Pharmaceuticals, Gilead Sciences, and Amgen, BB Biotech has once again established substantial positions in commercially established large companies for the first time in the current investment cycle. These holdings are intended to contribute stability and liquidity without diluting the company’s focus on innovation.

In addition, several mid- and small-cap companies were newly added to the portfolio, including Crinetics Pharmaceuticals, Enliven Therapeutics, Vaxcyte, Disc Medicine, Ultragenyx, Monte Rosa Therapeutics, and Oruka Therapeutics. Positions in Viridian Therapeutics and Krystal Biotech were increased following positive clinical and commercial signals, while Neurocrine Biosciences, Wave Life Sciences, and Maze Therapeutics were completely divested. Amicus Therapeutics and Avidity Biosciences left the portfolio following completed acquisitions. Atrium Therapeutics was added as a spin-off from Novartis’ acquisition of Avidity.

Capital was also released on the winning side: Revolution Medicines and Ionis Pharmaceuticals, both with strong performance and significantly increased valuations, were reduced proportionally.

Investment guidelines expanded: Up to 50 positions in the future

The most strategically significant change is the adjustment of the investment guidelines. The target portfolio range has been expanded from 20 to 35 to 20 to 50 listed companies. BB Biotech justifies this move with a growing number of clinically differentiated opportunities and increased research capabilities, which allow for broader coverage without sacrificing analytical depth. The conviction-driven investment approach with a strong focus on core positions will be maintained.

The expanded framework is accompanied by an increase in personnel: In the first quarter, BB Biotech hired a new senior analyst in the USA, who will specifically strengthen the coverage of large-cap biopharmaceutical companies.

AI is being integrated into the investment process

In parallel, BB Biotech is driving forward the digitalization of its own investment process. The company is developing its own AI-powered analytics platform, which will systematically link scientific data, clinical signals, and regulatory insights. The use of agent-based AI aims for continuous portfolio monitoring and more structured risk assessment. The goal is a more scalable investment architecture that combines human expertise with machine-generated insights.

Inclusion in the SPI Select Dividend 20

BB Biotech also received confirmation from the index during the reporting quarter: Effective March 23, the company was included in the SPI Select Dividend 20 Index. This inclusion recognizes the dividend policy pursued since 2013, according to which 5 percent of the average share price in December is distributed annually. A dividend of CHF 2.25 per share was paid in March for the 2025 financial year.

Outlook: A packed calendar of clinical impulses

The macroeconomic outlook remains challenging for the rest of the year. Trade uncertainties, geopolitical shifts, and changing interest rate expectations are weighing on equity markets. BB Biotech views direct tariff risks for its portfolio companies as limited, but considers indirect effects via investor sentiment, discount rates, and financing conditions to be significant.

The portfolio itself is positioned to capitalize on a busy calendar of clinical and regulatory events. Several core holdings are approaching key value-defining milestones – from regulatory approvals to late-stage development data. Management says this concentration of potential share price catalysts is the result of a targeted portfolio restructuring over the past twelve months.

__

(Featured image by Nicholas Cappello via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in investrends.ch. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.